Broadwind Stockholders Re-Elect All Seven Incumbent Director Nominees at 2023 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
Ziopharm Recommends Shareholders Return the
GREEN Consent Revocation Card
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s
GREEN Consent Revocation Card.
s
Independent financial analysts widely recognize this progress:
“ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.”
2
“By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.”
3
“We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12).ZIOP has executed well over 2020 in curating immune receptors from its own libraries and it is moving forward its wholly owned program.”
4
The Company continues to urge shareholders to support Ziopharm’s continued progress and protect the value of their investment by signing and returning the